Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.'s share was trading at $8.67 as of April 20th. NVAX’s trailing P/E was 3.36 according to Yahoo Finance.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. NVAX is positioned as a deeply misunderstood vaccine company that the market continues...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.